AGC patients showing progression after S-1 monotherapy for advanced cancer or recurrence within 6 months after completion of S-1 adjuvant therapy were randomly allocated to CPT-11 / CDDP ( CPT-11 , 60 mg/m ( 2 ) ; CDDP , 30 mg/m ( 2 ) , q2w ) or CPT-11 ( 150 mg/m ( 2 ) , q2w ) .